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http://dxObjectives: Purified antithrombin supplementation in cardiac surgery has been suggested for the treatment of
heparin resistance and the prevention of thromboembolic complications. This study is a randomized controlled
trial of preoperative purified antithrombin supplementation, with the primary end point of avoiding low (<58%)
postoperative antithrombin activity levels and secondary end points including avoidance of heparin resistance,
clinical outcome, and safety end points.
Methods: Two hundred patients were randomly allocated to the antithrombin group and the control group.
Patients in the antithrombin group received a dose of purified antithrombin to reach an antithrombin activity
value of 120%, whereas patients in the control group did not receive antithrombin.
Results: The antithrombin activity values were significantly higher in the antithrombin group at all postoperative
determinations until discharge.Antithrombin activity levels<58% at admission to the intensive careunitwere found
in 26.6% of patients in the control group versus none in the antithrombin group (P¼ .001). Heparin resistance rate
was significantly (P¼ .001) higher in the control group (38.2%) versus the antithrombin group (17%). Patients in
the antithrombin group had a significant but clinically irrelevant (8mL/hour) higher postoperative bleeding, with no
differences in transfusion rates.Nodifferenceswere found for clinical outcomes, andno safety issueswere identified.
Conclusions: Preoperative antithrombin supplementation prevents heparin resistance and avoids excessive
postoperative decrease of antithrombin activity. (J Thorac Cardiovasc Surg 2013;145:1393-9)Antithrombin (AT) supplementation in cardiac operations
with cardiopulmonary bypass (CPB) is still an open issue.
Low levels of AT before and during CPB are associated with
a poor response to heparin, commonly defined as ‘‘heparin re-
sistance’’ (HR), which occurs at a variable rate between 10%
and 30% depending on the definition.1-4 The use of purified
AT to treat HR has been suggested as an alternative to fresh
frozen plasma administration.5 Four randomized controlled
trials demonstrated the efficacy of purified AT for the treat-
ment of HR before or during CPB,6-9 and the recently
released update (2011) of the Society of Thoracic Surgeons
and Society of Cardiovascular Anesthesiologists Guidelines
on Blood Conservation Clinical Practice10 states that HR
should be treatedwithAT concentrates before CPB (class IA).
During CPB, thrombin generation is mainly triggered by
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The Journal of Thoracic and Carprocedure and less importantly by contact with foreign sur-
faces. Heparin may only partially suppress thrombin genera-
tion, and the excessive hemostatic systemactivationmay lead
to coagulation factors consumption.Moreover, AT consump-
tion during CPB may trigger postoperative thromboembolic
complications, in presence of high thrombin generation. One
observational study demonstrated an inverse relationship
between postoperative AT levels and the incidence of a num-
ber of complications, including thromboembolic events,
adverse neurologic events, bleeding, and prolonged intensive
care unit (ICU) stay.11 Furthermore, guidelines10 place AT
supplementation for the prevention of thromboembolic com-
plications in selected patient populations in class IIB.
In the light of these arguments, it is reasonable to believe
that preoperative supplementation with purified AT may
represent a viable strategy for decreasing the hemostatic
system dysregulation, preventing HR, and reducing postop-
erative morbidity in cardiac surgery operations with CPB.
This study is a phase II randomized controlled trial on
pre-CPB purified AT supplementation aimed to investigate
the effects of this treatment in maintaining postoperative AT
values within the normal range, avoiding HR, and limiting
postoperative complications.P
MMATERIALS AND METHODS
Study Design
This study is a phase II single center, single blinded, randomized,
controlled trial designed to evaluate preoperative AT supplementation in
patients undergoing cardiac surgery with CPB. The clinicians giving thediovascular Surgery c Volume 145, Number 5 1393
Abbreviations and Acronyms
AE ¼ adverse event
AT ¼ antithrombin
CPB ¼ cardiopulmonary bypass
HR ¼ heparin reistance
ICU ¼ intensive care unit
SAE ¼ serious adverse event
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Mtreatment were not blinded; patients and clinicians assessing outcome
measurements were not aware of patient allocation.
The study was approved by the local ethics committee and national
health authority and properly registered at a public trials registry, www.
clinicaltrial.gov (trial ID NCT00823082). Written informed consent was
obtained from all patients before their participation.
The study was supported by Instituto Grifols S.A. (Barcelona, Spain).
Representatives were involved in designing the study but not in collecting,
analyzing, or interpreting the data. They read and approved the final man-
uscript but had no influence in making the decision to submit for
publication.Study Population
Inclusion criteria were: male or female patient aged at least 18 years
needing an elective heart surgery with CPB. To be eligible, subjects had
to present a baseline ATactivity<100% and>60% and be willing to com-
ply with all aspects of the protocol, including blood sampling, for the total
duration of the study.
Exclusion criteria included heart transplant operations, nonelective sur-
gery, participation in another investigational study during the past 3months,
documented AT deficiency, history of anaphylactic reaction(s) to blood or
blood components, allergies to excipients, and pregnancy.
From June 2009 to April 2011 patients undergoing elective cardiac sur-
gerywith CPBwere considered for enrollment at a single institution (IRCCS
Policlinico San Donato, Milan, Italy). One thousand ninety patients were
evaluated for screening (Figure 1) of which 1407 patients did not meet the
eligibility criteria (136 patients suffered fromcongenital heart disease, 60 pa-
tients hadmissing baselineAT level values, 16 had baselineAT levels<60%,
1056 had baseline AT activity 100%, and 139 patients were enrolled in
other randomized controlled trials), and 377 patients declined to participate
orwerenot able togive consent because of their clinical condition.Screening,
eligibility, and enrollment of patients are shown in Figure 1.Study Interventions
The randomization schemewas electronically generated by an indepen-
dent biostatistician and delivered to the center in sealed numbered
envelopes.
The investigational drug (purified human plasma derived AT, Anbinex;
Instituto Grifols S.A., Barcelona, Spain) was administered immediately af-
ter anesthesia induction as a single dose targeted to achieve a level of 120%
according to the formula
ATðIUÞ ¼ ð120 actual AT activityÞ3ðweight in kgÞ30:8
Patients randomized to the control group did not receive any dose of the
study drug. Postoperative AT administration was excluded by the study
protocol.
The value of 120% was decided based on the fact that the normal AT
activity range is considered 80% to 120%,12 and that using chromogenic
tests the value of 120% is considered as the upper limit of the normal range
by the majority of the manufacturers, including the one providing the as-
says used in this study.1394 The Journal of Thoracic and Cardiovascular SurIntraoperative Anticoagulation
Unfractionated heparin was intraoperatively administered before CPB to
reach andmaintain a target activatedclotting timeof 450 secondsduringCPB.
The heparin loading dose was assessed using a heparin monitoring
system (Medtronic Inc, Minneapolis, Minn), which provided the estimated
dose to reach an activated clotting time of 450 seconds and the heparin sen-
sitivity index (seconds/IU/mL) as a measurement of the patient’s sensitivity
to heparin. The latter tests were performed before administration of the
study drug, and repeated in patients of the AT group after receiving the
study drug. In the AT group, the heparin loading dose was established
according to the post-AT administration test.
Further heparin doses during CPB were administered as a bolus of
100 IU/kg if needed to maintain the desired activated clotting time value.
Heparin was reversed with protamine sulphate at a 1:1 ratio with the
heparin loading dose; a second protamine dose (0.5 mg/kg) was adminis-
tered if required.
ATActivity Determinations
All ATactivity determinationswere performed in the same local hospital
laboratory with a coagulometer Sysmex CA-6000 (Toa Medical Electron-
ics, Milan, Italy) through a calibration curve prepared by serial dilution of
a human normal plasma pool and expressed as percentage of activity.
Data Collection and Time Points
Clinical data collected during this study were the usual ones routinely
collected in the institutional database: patient demographics, medical his-
tory, comorbidities, risk stratification according to the EuroSCORE, and
intraoperative details (eg, type of operation, CPB and aortic crossclamp
time duration, lowest hematocrit on CPB, heparin and protamine dose,
and heparin sensitivity index).
Laboratory data included complete blood count, biochemistry (eg,
serum creatinine and liver enzymes) and coagulation tests (eg, AT activity,
activated partial thromboplastin time, prothrombin time, international
normalized ratio, and fibrinogen).
Throughout the study clinical data were collected at 8 separate time
points: recruitment visit (within 14 days before the operation), preopera-
tively (the day of the operation), operatively (during the operation), at
ICU admission, on postoperative days 1 and 2, at ICU discharge, and at
the follow-up visit (1 month after the operation).
Study Outcomes: Assessment of Efficacy
The primary efficacy end points of the study were (1) AT activity levels
at ICU admission higher in the AT group versus control group and (2) lower
percentage of patients with AT activity<58% in the AT group versus
control group. The value of AT activity settled at 58% was not arbitrary,
being based on our previous study11 where we could identify this cut-off
value at the arrival in the ICU as the most specific and sensitive value
predicting a prolonged ICU stay.
AT levels were measured at the recruitment visit and postoperatively
immediately after the ICU admission, on postoperative days 1 and 2, and
at discharge from the ICU.
Secondary efficacy end points were: HR (failure to reach an activated
clotting time>450 seconds after a dose of up to 400 IU/kg heparin or to
maintain this value despite heparin supplementation of 100 IU/kg), blood
loss (in the first postoperative 12 hours), number of plasma and packed
red cells units needed during the ICU stay, mechanical ventilation duration
(hours), ICU and hospital stay (days), and prolonged (>7 days) ICU stay.
Additional secondary end pointswere related to the postoperative complica-
tion rate (safety outcomes), which included surgical re-exploration (due to
bleeding), low cardiac output syndrome (need for inotropic support>48
hours),myocardial infarction, adverse neurologic outcome, acute kidney in-
jury (peak serum creatinine level>2 mg/dL and twice the baseline), throm-
boembolic events (myocardial infarction, stroke, mesenteric infarction, or
peripheral or pulmonary thromboembolism), and in-hospital mortality.gery c May 2013
FIGURE 1. Flow diagram of enrollment, intervention allocation, and data analysis. AT, Antithrombin.
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MStudy Outcomes: Clinical Safety and Tolerability
Clinical safety and tolerability of the investigational drug was assessed
by monitoring vital signs, hematologic parameters, clinical chemistry pa-
rameters, and adverse events (AEs). Serious adverse events (SAEs) were
defined as a medical occurrence that resulted in death, was life-
threatening, prolonged the hospitalization, or resulted in persistent or
significant disability.
Viral safety included virology testing at the recruitment and follow-up
visit.
Statistical Analysis
The sample size was calculated at 200 patients (100 patients per group),
based on a 90% power to confirm the hypothesis that patients in the AT
group would maintain a mean AT activity value 10% higher (in absolute
value) than patients in the control group at the arrival in the ICU. This
calculation was based on 2-sided tests, and predicted mean values and stan-
dard deviation of AT activity taken from previous studies.11,13
Continuous data are summarized by using descriptive statistics; that is,
mean and standard deviation or median and range (minimum and maxi-
mum) according to their distribution. Categorical variables are summarized
by using frequency (counts) and percentages, with relative risk and 95%
confidence intervals when appropriate. Statistical tests applied in the effi-
cacy and safety analysis included parametric (Student t test, analysis of var-
iance for repeated measures, and linear and binary regression analysis) and
nonparametric tests (Mann-Whitney test). The primary end points were as-
sessed with an analysis of variance for repeated measures (end point: AT
activity higher in treatment arm) and relative risk analysis (lower rate of pa-
tients with<58%ATactivity at the arrival in the ICU in the treatment arm).
A receiver operating characteristics analysis with the area under the
curve measurement was anticipated to assess the predictive value of post-
operative ATactivity in both treatment arms. Other statistical tests used for
post hoc analyses included best fit between continuous variables using
linear and nonlinear regression analyses.
RESULTS
The 2 groups’ details are shown in Table 1. Patients in the
AT group received a significantly lower dose of heparin toThe Journal of Thoracic and Carestablish andmaintain anticoagulation for CPB, and a corre-
spondent significantly lower dose of protamine to return to
the baseline activated clotting time.Within the AT group the
heparin sensitivity index significantly (P<.001) increased
after the administration of the study drug.
All patients who received the study drug were included in
the analysis. For 5 patients in the control group the AT value
at the arrival to the ICU was not determined. These patients
were not included in the primary end points efficacy analy-
sis but remained in the secondary end points efficacy anal-
ysis and safety analysis. One patient in the control group
received a therapeutic dose of purified AT during the ICU
stay according to medical judgment and was thus excluded
from the efficacy analysis.
All patients completed the study protocol until ICU and
hospital discharge. Follow-up at 1 month was completed
by 146 patients (75% of patients discharged from the
hospital). This relatively low adherence to the 1-month
follow-up was mainly due to patients living in regions other
than Lombardy, who were unwilling to travel back to our
institution.
Patients in the AT group received a median dose of 1800
IU (range, 1000-4000 IU) purified AT and the highest 90th
percentile received was 3000 to 4000 IU.
Efficacy Assessment
Both of the primary efficacy end points were successfully
reached. Postoperative AT values analyzed for repeated
measures demonstrated a significant (P ¼ .002) between
group difference in favour of the AT group. This effect
was found at any postoperative point in time except for
the follow-up visit (Figure 2). Twenty-five patientsdiovascular Surgery c Volume 145, Number 5 1395
TABLE 1. Main pre- and intraoperative variables in the 2 groups
Variable
No. or mean ± SD
Control group
(n ¼ 100)
AT group
(n ¼ 100)
P
value
Age (y) 67.8  11.2 66.9  10.5 .890
Male gender 75 83 .224
Weight (kg) 78.3  17.3 80.5  17.5 .374
Hypertension 86 71 .009
Hypercholesterolemia 56 47 .203
Left ventricular ejection
fraction (%)
53.9  9.6 54.3  10.7 .766
Recent (30 d) myocardial
infarction
20 10 .073
Unstable angina (current) 5 11 .613
Congestive heart failure
(current)
2 3 .651
Active endocarditis 1 1 1.000
Chronic dialysis 1 0 .316
Chronic obstructive
pulmonary disease
8 13 .357
Previous neurologic accident 5 4 .733
Previous pulmonary
embolism
2 2 1.000
Peripheral vascular disease 13 12 .831
Previous cardiovascular
surgery
5 6 .756
Diabetes on medication 21 28 .324
Severe liver disease 2 3 .651
Logistic EuroSCORE 5.9  4.7 5.3  5.2 .459
Oral anticoagulant therapy 17 16 .849
Heparin therapy (current) 25 29 .633
Serum creatinine (mg/dL) 1.04  0.82 1.02  0.35 .814
Hemoglobin (mg/dL) 12.6  1.65 12.5  1.56 .545
Platelet count
(31000 cells/mL)
191  55 185  62 .475
Fibrinogen (mg/dL) 337  103 311  88 .062
Activated partial
thromboplastin time (s)
31.1  4.4 32.8  9.5 .108
International normalized ratio 1.17  0.14 1.18  0.13 .602
Isolated coronary operation 50 40 .155
Isolated valve operation 31 26 .436
Coronary þ valve operation 12 20 .127
Others 7 14 .112
CPB duration (min) 83.2  33.6 84.1  35.6 .858
Aortic crossclamp
duration (min)
58.4  29.5 60.8  30.2 .583
Total heparin dose
(3100 IU)
271  85 220  67 .001
Total protamine dose (mg) 268  69 227  57 .001
Lowest hematocrit on
CPB (%)
26.3  4.1 27.0  3.2 .158
HSI (baseline) (sec/IU/mL) 94.8  24 95.5  29 .895
HSI after purified AT
(s/IU/mL)
Not measured 120  41 .001*
SD, Standard deviation; AT, antithrombin; EuroSCORE, European System for Car-
diac Operative Risk Evaluation; CPB, cardiopulmonary bypass; HIS, heparin sensi-
tivity index. *Within the AT group, after vs before purified AT administration.
FIGURE 2. Antithrombin (AT) activity levels during the study period. SD,
Standard deviation; ICU, intensive care unit.
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M(26.6%) in the control group had an ATactivity level<58%
versus none (0%) in the AT group (P<.001).
The secondary efficacy and safety end points evaluated
during the entire follow-up period are depicted in
Figure 3. Patients in the AT group had a significantly
(P<.001) lower rate of heparin resistance. No significant
differences were found with respect to the total or specific
complications rates for binary events. There were 3 adverse
neurologic events in the AT group (1 anoxic coma postcar-
diac arrest in the ward and 2 cerebral hemorrhages) and no
events in the control group. These differences were not
statistically significant.
Patients in the AT group (Table 2) had a significantly
higher postoperative bleeding that was of little clinical rel-
evance (8 mL/hour); no differences were found with respect
to the number of packed red cells, fresh frozen plasma, and
platelet concentrates units transfused. Duration of mechan-
ical ventilation, ICU stay, and overall hospital stay were not
significantly different between study groups.
Overall, therewas a trend toward an increased incidence of
complications in theAT group (22 out of 99 vs 31 out of 100).
Safety Assessment
There were 528 AEs in the AT group and 443 in the
control group. A total of 64 SAEs in 32 patients occurred
in the AT group and 51 in 29 patients in the control group.
Three AEs/SAEs were considered as potentially related
to the study drug, of which 2 were rated as SAEs: 1 case
of cerebral hemorrhage (cause-effect relationship: doubt-
ful); and 1 case of hepatitis C virus seroconversion
(cause-effect relationship: possible). In the latter case an in-
determinate (‘doubtful’) positive result for hepatitis C virus
antibody was found at the follow-up visit after a negative
baseline hepatitis C virus antibody result. Although the pa-
tient did not receive any transfusions during surgery he did
present other important risk factors that could explain this
seropositivity: surgery itself and a close relative (wife)
that was hepatitis C virus positive.gery c May 2013
FIGURE 3. Secondary end points (clinical outcomes). Relative risk (RR) with 95% confidence intervals (95% CIs). AT, Antithrombin; PRC, packed red
cells; FFP, fresh frozen plasma; ICU, intensive care unit.
Ranucci et al Perioperative ManagementPost Hoc Analysis: AT Activity at the Arrival to the
ICU and Postoperative Outcome
We conducted a post hoc analysis to determine the rela-
tionship between AT activity immediately at the arrival to
the ICU and the length of ICU stay in our study population,
taking into account the treatment arm.
In Figure 4 the association between ICU length of stay
and AT activity at the arrival to the ICU is depicted. Differ-
ent nonlinear regression analyses were performed to iden-
tify the best fit for the relationship. Given the non-normal
distribution of the ICU stay variable, a Poisson weighting
was applied to the different models tested. The nonlinear
equation with the best fit was a quadratic, U-shaped
equation, where the length of ICU stay is dependent on
the AT activity according to the equation:
ICU stayðdaysÞ ¼ 12:72 0:283AT activity
þ0:00183ðAT activityÞ2
where the weighted R2 was 0.165 (P value for association
<.001).TABLE 2. Outcome parameters (continuous variables)
Variable (median and
range)
Control group
(n ¼ 99)
AT group
(n ¼ 100)
P
value
Blood loss (mL/12 h) 350 (100-1875) 450 (50-1950) .011
No. of PRCs units transfused 0 (0-11) 0 (0-10) .304
No. of FFP units transfused 0 (0-9) 0 (0-6) .106
No. of PLT units transfused 0 (0-13) 0 (0-5) .379
Mechanical ventilation (h) 12 (4-110) 15 (3-450) .367
ICU stay (d) 2 (1-13) 2 (1-22) .372
Hospital stay (d) 7 (4-27) 7 (4-32) .556
AT, Antithrombin; PRCs, packed red cells; FFP, fresh frozen plasma; PLT, platelet
concentrates; ICU, intensive care unit.
The Journal of Thoracic and CarPatients in the control group had a significant negative
association of the AT activity at the arrival in the ICU
with the presence of a prolonged (>7 days) ICU stay. An
receiver operating characteristics analysis (Figure 5) dem-
onstrated the predictive value of the ATactivity at the arrival
in the ICU for prolonged ICU stay, with an area under theFIGURE 4. Scatterplot showing the relationship between intensive care
unit (ICU) length of stay and antithrombin (AT) activity at ICU admission.
Solid line represents the quadratic regression fit of the relationship and the
broken line its 95% confidence limits. Open diamonds, AT group; black
dots, control group.
diovascular Surgery c Volume 145, Number 5 1397
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Mcurve of 0.821 and a cut-off value settled at an AT activity
<58% (75% sensitivity and 73% specificity).
DISCUSSION
This study fulfilled the primary efficacy end points dem-
onstrating that (1) preoperative supplementation with puri-
fied AT maintains AT activity at a significantly higher level
than untreated patients upon ICU admission and during the
first 2 postoperative days, and (2) no patients treated with
purified AT experienced low (<58%) levels of AT activity
during the postoperative course. Additional findings (sec-
ondary end points) are that the heparin resistance rate is sig-
nificantly lower in AT-treated patients, that lower doses of
heparin were required to reach and maintain an activated
clotting time >450 seconds in AT-treated patients, and
that AT supplementation significantly increased the heparin
sensitivity of these patients.
No significant differences with respect to postoperative
outcomes were observed between the 2 study groups,
except a significant, but clinically irrelevant higher postop-
erative bleeding in AT-treated patients. This study did not
raise safety issues and the rate of AEs/SAEs was consistent
with the expected findings in this patient population. How-
ever, there was a trend toward a higher rate of complications
in the AT-treated patients that may deserve further attention.
AT supplementation in heparin-resistant patients is
already established as a first-choice treatment6-10
preferred over fresh frozen plasma. The novelty of our
study is the pre-emptive use of purified AT, aimed to main-
tain the postoperative AT activity at a normal value.FIGURE 5. Receiver operating characteristic analysis for antithrombin
(AT) activity at the intensive care unit admission as a predictor of prolonged
(>7 days) intensive care unit stay in control group patients.
1398 The Journal of Thoracic and Cardiovascular SurPrevious observational studies have highlighted that low
levels of AT activity at the arrival to the ICU and during
the first postoperative days were associated with bad out-
comes11 and major adverse cardiovascular events.14 Our
phase II randomized controlled study was not powered to
detect clinical differences in postoperative outcomes and
major adverse cardiovascular events between the 2 arms.
However, a trend toward fewer thromboembolic events
was found in the AT group, at the expense of a slightly
higher bleeding tendency.
Previous studies have already raised the concern that AT
supplementation may result in a higher postoperative bleed-
ing tendency.13 This is not surprising given the well-known
anticoagulant properties of AT.
Some additional information may come from the within
group analysis conducted in this trial, focused on the asso-
ciation between AT activity at ICU admission and length of
ICU stay. Lacking the power for specific clinical outcomes
assessment, the length of ICU stay may be considered as
a surrogate for a composite number of moderate to severe
complications that result in a prolonged ICU stay, as already
demonstrated in a previous study.11
The analysis of patients in the control group confirms
previous findings that the lower the AT activity level at
ICU admission is, the higher the risk for a prolonged (>7
days) ICU stay is. This partially contradicts the findings
of other studies,14 again strengthening the hypothesis that
low AT values anticipate, and do not follow the AEs. Inter-
estingly, the critical value of AT activity<58% at ICU
admission was confirmed in this study.
Some of the patients in the AT group demonstrated a pro-
longed ICU stay with high values (>95%) of AT activity at
ICU admission. This trend introduces the hypothesis that
some of the AT-treated patients may have experienced an
AT overcorrection. Despite the application of an equation
based on weight and preoperative AT activity, there were
some patients with probably excessive postoperative AT ac-
tivity values, owing to the administration of a higher AT
dose. However, ourAT-treated patients did not receive unusu-
ally high AT doses, with only 10% receiving>3000 units,
a dose lower than those used in previous studies using purified
(50 IU/kg)15 or recombinant AT (75 IU/kg).7,8 Therefore, this
study raises the hypothesis that a preoperative target value of
120% may be excessive, especially in absence of the
recognized factors increasing AT consumption (eg, CPB
duration, opening of the cardiac chambers, and advanced
age). The achievement of this potentially excessive target
value may be responsible for the trend towards a higher
complication rate (namely bleeding related) in the AT group.
The overall analysis of the U-shaped relationship
between AT activity at ICU admission and ICU length of
stay highlights that patients with shorter ICU stays belong
to an area with AT activity between 70% and 95% at ICU
admission, either spontaneously reached by untreatedgery c May 2013
Ranucci et al Perioperative Managementpatients or achieved through AT supplementation in treated
patients. This range may probably represent a correct bal-
ance between the risk of bleeding and the risk of thrombotic
events. Values below this range may probably place the
patient in an area at risk for excessive thrombin generation
and micro/macrovascular thrombosis; conversely, values
above this range are associated with a more pronounced
risk of bleeding events.
Study Limitations
There are some limitations in this randomized, controlled
trial. First of all, due to the need for adjusting the heparin
dose to the AT activity, the study was not double-blinded.
Moreover, given the fact that postoperative AT activity is
routinely measured in our institution, it was not possible
to blind the clinicians in charge for the postoperative course.
Finally, the follow-up was not completed by a considerable
amount of patients. This was mainly due to the presence of
many patients referred from external, out-of-region
hospitals.
Future Perspectives
This phase II trial may open the possibility to run a phase
III trial powered to address more clinically relevant end
points (ie, major morbidity and mortality). Moreover, we
think that our study may offer a useful advice for the design
of future trials, which should avoid ‘‘overcorrection’’ of AT
values, which probably induced some of the observed com-
plications in the AT-treated patients. A more reasonable
target for preoperative AT activity could be not higher
than 100%.
Alternatively, future trials may focus more on patients
with a lower preoperative AT activity (ie,<80%), or at
higher risk to experience a huge intraoperative loss of AT
activity (ie, prolonged CPB>120 minutes).
In conclusion, our study confirms the role of preoperative
AT supplementation for the prevention of heparin resis-
tance, demonstrating that this strategy avoids that the pa-
tients may experience very low postoperative AT activity
values (that are associated with a prolonged ICU stay).
We believe that our data provide clinically relevant infor-
mation for further phase III studies focused on clinicalThe Journal of Thoracic and Caroutcomes, particularly as a guide for the choice of the ade-
quate purified AT dose.References
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